2′-O-acetyl-6-O-methyl-erythromycin A 11,12-cyclic carbonate | 122929-11-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2′-O-acetyl-6-O-methyl-erythromycin A 11,12-cyclic carbonate
• 英文别名: 2'-O-acetyl-6-O-methyl-erythromycin A 11,12-cyclic carbonate
• CAS: 122929-11-7
• 化学式: C₄₁H₆₉NO₁₅
• 分子量: 815.997
• InChiKey: XJSVIUZGFQZROG-HSOCBEQRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.19
• 重原子数：
  57.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  184.05
• 氢给体数：
  1.0
• 氢受体数：
  16.0

反应信息

• 作为反应物：
  描述：

  2′-O-acetyl-6-O-methyl-erythromycin A 11,12-cyclic carbonate 在 三乙基硅基三氟甲磺酸酯 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 6-O-methyl-4″-O-(6-deoxy-3-dimethylamino-β-D-desosaminyl)erythromycin A11,12-cyclic carbonate
  参考文献：
  名称：

  Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities

  摘要：

  A series of new 4"-O-desosaminyl clarithromycin derivatives were designed and synthesized. The efficient synthesis routes of 6-deoxy-desosamine donors 8 and 11 were developed and the methodology of glycosylation of clarithromycin 4"-OH with desosamine was studied. The activities of the target compounds were tested against a series of macrolide-sensitive and macrolide-resistant pathogens. Some of them showed activities against macrolide sensitive pathogens, and compounds 19 and 22 displayed significant improvement of activities against sensitive pathogens and two strains of MRSE, which verified the importance of desosamine in the interaction of macrolide and its receptor, and offered valuable information of the SAR of macrolide 4"-OH derivatives. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.083
• 作为产物：
  描述：

  克拉霉素 在 吡啶 作用下， 以 氯仿 、 丙酮 为溶剂， 反应 3.92h， 生成 2′-O-acetyl-6-O-methyl-erythromycin A 11,12-cyclic carbonate
  参考文献：
  名称：

  [EN] C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE
  [FR] DÉRIVÉ DE MACROLIDE SUBSTITUÉ EN POSITION C-4"

  摘要：

  一种由化学式（I）表示的大环内酯化合物，对红霉素耐药细菌有效（例如，耐药的肺炎球菌、链球菌和支原体）。

  公开号：

  WO2012115256A1

文献信息

• Ether linked macrolides useful for the treatment of microbial infections
  申请人：Alihodzic Sulejman

  公开号：US20060258600A1

  公开（公告）日：2006-11-16

  The present invention relates to 14- or 15-membered macrolides substituted at the 4″ position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

  本发明涉及在式(I)的4″位置被取代的14-或15-元大环内酯及其药学上可接受的衍生物，以及它们的制备过程和在人体或动物体内治疗或预防全身或局部微生物感染中的用途。